Sialorrhoea - Pipeline Insight, 2021
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Sialorrhoea – Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Sialorrhoea pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Sialorrhoea: Overview
Sialorrhea, drooling or excessive salivation is a common problem in neurologically impaired children and in adults who have Parkinson's disease or have had a stroke. It is most commonly caused by poor oral and facial muscle control. Sialorrhea can lead to significant physical and psychosocial complications, including perioral chapping, dehydration, infection, foul odor, stigmatization, and increased dependency and level of care, all of which can create an additional burden for these medically complicated patients. Sialorrhea usually is caused by neuromuscular dysfunction, hypersecretion, sensory dysfunction, or anatomic (motor) dysfunction. The most common cause is neuromuscular dysfunction. Anterior sialorrhea is diagnosed by the observation of excessive drooling. Posterior sialorrhea can be suggested by the history of choking and repeated pneumonias. Treatment for Sialorrhea range from conservative (i.e., observation, postural changes, biofeedback) to more aggressive measures such as medication, radiation, and surgical therapy.
'Sialorrhoea - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Sialorrhoea pipeline landscape is provided which includes the disease overview and Sialorrhoea treatment guidelines. The assessment part of the report embraces, in depth Sialorrhoea commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Sialorrhoea collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Sialorrhoea report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Sialorrhoea Emerging Drugs
Further product details are provided in the report
Sialorrhoea: Therapeutic Assessment
This segment of the report provides insights about the different Sialorrhoea drugs segregated based on following parameters that define the scope of the report, such as:
Sialorrhoea: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Sialorrhoea therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sialorrhoea drugs.
Sialorrhoea Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Sialorrhoea – Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Sialorrhoea pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Sialorrhoea: Overview
Sialorrhea, drooling or excessive salivation is a common problem in neurologically impaired children and in adults who have Parkinson's disease or have had a stroke. It is most commonly caused by poor oral and facial muscle control. Sialorrhea can lead to significant physical and psychosocial complications, including perioral chapping, dehydration, infection, foul odor, stigmatization, and increased dependency and level of care, all of which can create an additional burden for these medically complicated patients. Sialorrhea usually is caused by neuromuscular dysfunction, hypersecretion, sensory dysfunction, or anatomic (motor) dysfunction. The most common cause is neuromuscular dysfunction. Anterior sialorrhea is diagnosed by the observation of excessive drooling. Posterior sialorrhea can be suggested by the history of choking and repeated pneumonias. Treatment for Sialorrhea range from conservative (i.e., observation, postural changes, biofeedback) to more aggressive measures such as medication, radiation, and surgical therapy.
'Sialorrhoea - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Sialorrhoea pipeline landscape is provided which includes the disease overview and Sialorrhoea treatment guidelines. The assessment part of the report embraces, in depth Sialorrhoea commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Sialorrhoea collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Sialorrhoea R&D. The therapies under development are focused on novel approaches to treat/improve Sialorrhoea.
This segment of the Sialorrhoea report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Sialorrhoea Emerging Drugs
- NT0502: Aytu BioPharma
Further product details are provided in the report
Sialorrhoea: Therapeutic Assessment
This segment of the report provides insights about the different Sialorrhoea drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Sialorrhoea
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Sialorrhoea: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Sialorrhoea therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sialorrhoea drugs.
Sialorrhoea Report Insights
- Sialorrhoea Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Sialorrhoea drugs?
- How many Sialorrhoea drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Sialorrhoea?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Sialorrhoea therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Sialorrhoea and their status?
- What are the key designations that have been granted to the emerging drugs?
Introduction
Executive Summary
Sialorrhoea: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Sialorrhoea – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Sialorrhoea companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Sialorrhoea Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
Comparative Analysis
OC oral solution: Orient pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
NT0502: Aytu BioPharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical stage products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Sialorrhoea Key Companies
Sialorrhoea Key Products
Sialorrhoea- Unmet Needs
Sialorrhoea- Market Drivers and Barriers
Sialorrhoea- Future Perspectives and Conclusion
Sialorrhoea Analyst Views
Sialorrhoea Key Companies
Appendix
Executive Summary
Sialorrhoea: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Sialorrhoea – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Sialorrhoea companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Sialorrhoea Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
Comparative Analysis
OC oral solution: Orient pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
NT0502: Aytu BioPharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical stage products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Sialorrhoea Key Companies
Sialorrhoea Key Products
Sialorrhoea- Unmet Needs
Sialorrhoea- Market Drivers and Barriers
Sialorrhoea- Future Perspectives and Conclusion
Sialorrhoea Analyst Views
Sialorrhoea Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Sialorrhoea
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Sialorrhoea
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Sialorrhoea
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Sialorrhoea
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
